Alginomics, a company specializing in the development of ribonucleic acid (RNA)-based gene therapies, announced on the 19th that it has received research and development (R&D) funding (Research Fund) under its license-out agreement for a hereditary hearing loss treatment with global pharmaceutical company Eli Lilly.


In May last year, Alginomics signed a global license agreement with Eli Lilly for the development and commercialization of a hereditary hearing loss treatment, with a total potential contract value of more than 1.3 billion dollars (approximately 2 trillion won). The receipt of this research funding signifies that the jointly agreed R&D plan between the two companies has now entered the full implementation phase following the signing of the contract.

Alginomics Receives Hereditary Hearing Loss Research Funding from Eli Lilly View original image

The research funding received this time is not included in the total contract value and was paid separately from the upfront payment as R&D-focused funding. While the specific amount has not been disclosed in accordance with mutual agreement between the two companies, Alginomics explained that it is a substantial sum sufficient to enable stable research on the relevant pipeline. Based on this funding, the company plans to accelerate R&D for its hereditary hearing loss program and further advance its RNA correction platform.


Alginomics possesses a platform technology called the trans-splicing ribozyme, which corrects genetic information at the RNA level. Its key feature is the ability to replace disease-causing mutant RNA with normal RNA without directly editing DNA. The technology is regarded as having differentiated competitiveness in terms of safety, multi-site correction, and precise regulation of gene expression.


The company stated, "This research funding is more than a simple financial achievement; it is a meaningful milestone demonstrating that Alginomics' RNA correction platform has passed the rigorous verification of a global big pharma and has entered a substantive R&D stage," adding, "Starting with hearing loss disorders in collaboration with Lilly, we plan to seek to expand the scope of cooperation to various intractable diseases, including those of the central nervous system (CNS)."



Meanwhile, Alginomics was listed on the KOSDAQ market in December last year and is currently developing multiple gene therapy pipelines targeting cancer, Alzheimer's disease, retinitis pigmentosa, Rett syndrome, and other indications.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing